Last reviewed · How we verify
Trastuzumab or Lapatinib
At a glance
| Generic name | Trastuzumab or Lapatinib |
|---|---|
| Sponsor | Azienda Ospedaliera Ordine Mauriziano di Torino |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] (PHASE3)
- Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
- Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy (EARLY_PHASE1)
- A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (PHASE2)
- T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis (PHASE2)
- Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery (PHASE3)
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer (PHASE2)
- A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzumab or Lapatinib CI brief — competitive landscape report
- Trastuzumab or Lapatinib updates RSS · CI watch RSS
- Azienda Ospedaliera Ordine Mauriziano di Torino portfolio CI